Cargando…
Efficacy of pembrolizumab for advanced/metastatic melanoma: a meta-analysis
This study evaluates the efficacy of pembrolizumab for the treatment of advanced/metastatic melanoma. The literature search was conducted in electronic databases for studies that evaluated the efficacy and safety of pembrolizumab either alone or in combination with other treatments advanced/metastat...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
De Gruyter
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7706128/ https://www.ncbi.nlm.nih.gov/pubmed/33313405 http://dx.doi.org/10.1515/med-2020-0110 |
_version_ | 1783617089276215296 |
---|---|
author | Zhang, Qi Huo, Geng-wei Zhang, Hong-zhen Song, Ying |
author_facet | Zhang, Qi Huo, Geng-wei Zhang, Hong-zhen Song, Ying |
author_sort | Zhang, Qi |
collection | PubMed |
description | This study evaluates the efficacy of pembrolizumab for the treatment of advanced/metastatic melanoma. The literature search was conducted in electronic databases for studies that evaluated the efficacy and safety of pembrolizumab either alone or in combination with other treatments advanced/metastatic melanoma patients. Random-effects meta-analyses were performed to achieve pooled effect sizes of response and survival rates. The overall objective response rate (ORR) was 34.2% [95% confidence interval (CI): 30.4, 38.0]. However, ORR differed with respect to the history of prior systemic therapy. ORR was lower in studies with over 50% patients with prior therapy (25.5% [22.4, 28.5]) than in studies with under 50% patients with prior therapy (40.1% [34.1, 46.1]). ORR was higher in pembrolizumab monotherapy (32.9% [28.1, 37.7]) than in pembrolizumab–ipilimumab combination (27.6% [24.0, 31.2]). Overall ORR was inversely associated with visceral metastasis and prior systemic therapy. With pembrolizumab treatment, either alone or in combination, the progression-free survival (PFS) was 5.73 months; 12-, 24-, and 60-month PFS rate were 44%, 27%, and 25%, respectively; and 12-, 24-, and 60-month overall survival rates were 65%, 50%, and 41%, respectively. The percentage of AEs that led to treatment discontinuation was 13%. Pembrolizumab monotherapy is a valuable option for the treatment of advanced/metastatic melanoma patients. |
format | Online Article Text |
id | pubmed-7706128 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | De Gruyter |
record_format | MEDLINE/PubMed |
spelling | pubmed-77061282020-12-10 Efficacy of pembrolizumab for advanced/metastatic melanoma: a meta-analysis Zhang, Qi Huo, Geng-wei Zhang, Hong-zhen Song, Ying Open Med (Wars) Research Article This study evaluates the efficacy of pembrolizumab for the treatment of advanced/metastatic melanoma. The literature search was conducted in electronic databases for studies that evaluated the efficacy and safety of pembrolizumab either alone or in combination with other treatments advanced/metastatic melanoma patients. Random-effects meta-analyses were performed to achieve pooled effect sizes of response and survival rates. The overall objective response rate (ORR) was 34.2% [95% confidence interval (CI): 30.4, 38.0]. However, ORR differed with respect to the history of prior systemic therapy. ORR was lower in studies with over 50% patients with prior therapy (25.5% [22.4, 28.5]) than in studies with under 50% patients with prior therapy (40.1% [34.1, 46.1]). ORR was higher in pembrolizumab monotherapy (32.9% [28.1, 37.7]) than in pembrolizumab–ipilimumab combination (27.6% [24.0, 31.2]). Overall ORR was inversely associated with visceral metastasis and prior systemic therapy. With pembrolizumab treatment, either alone or in combination, the progression-free survival (PFS) was 5.73 months; 12-, 24-, and 60-month PFS rate were 44%, 27%, and 25%, respectively; and 12-, 24-, and 60-month overall survival rates were 65%, 50%, and 41%, respectively. The percentage of AEs that led to treatment discontinuation was 13%. Pembrolizumab monotherapy is a valuable option for the treatment of advanced/metastatic melanoma patients. De Gruyter 2020-06-10 /pmc/articles/PMC7706128/ /pubmed/33313405 http://dx.doi.org/10.1515/med-2020-0110 Text en © 2020 Qi Zhang et al., published by De Gruyter http://creativecommons.org/licenses/by/4.0 This work is licensed under the Creative Commons Attribution 4.0 International License. |
spellingShingle | Research Article Zhang, Qi Huo, Geng-wei Zhang, Hong-zhen Song, Ying Efficacy of pembrolizumab for advanced/metastatic melanoma: a meta-analysis |
title | Efficacy of pembrolizumab for advanced/metastatic melanoma: a meta-analysis |
title_full | Efficacy of pembrolizumab for advanced/metastatic melanoma: a meta-analysis |
title_fullStr | Efficacy of pembrolizumab for advanced/metastatic melanoma: a meta-analysis |
title_full_unstemmed | Efficacy of pembrolizumab for advanced/metastatic melanoma: a meta-analysis |
title_short | Efficacy of pembrolizumab for advanced/metastatic melanoma: a meta-analysis |
title_sort | efficacy of pembrolizumab for advanced/metastatic melanoma: a meta-analysis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7706128/ https://www.ncbi.nlm.nih.gov/pubmed/33313405 http://dx.doi.org/10.1515/med-2020-0110 |
work_keys_str_mv | AT zhangqi efficacyofpembrolizumabforadvancedmetastaticmelanomaametaanalysis AT huogengwei efficacyofpembrolizumabforadvancedmetastaticmelanomaametaanalysis AT zhanghongzhen efficacyofpembrolizumabforadvancedmetastaticmelanomaametaanalysis AT songying efficacyofpembrolizumabforadvancedmetastaticmelanomaametaanalysis |